Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Cancer. 2010 Apr 12;9:75. doi: 10.1186/1476-4598-9-75.

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Author information

  • 1Institute for Cancer Research and Treatment, University of Torino Medical School, 10060 Candiolo (Torino), Italy.

Abstract

In recent years, tyrosine kinases (TKs) have been recognized as central players and regulators of cancer cell proliferation, apoptosis, and angiogenesis, and are therefore considered suitable potential targets for anti-cancer therapies. Several strategies for targeting TKs have been developed, the most successful being monoclonal antibodies and small molecule tyrosine kinase inhibitors. However, increasing evidence of acquired resistance to these drugs has been documented, and extensive preclinical studies are ongoing to try to understand the molecular mechanisms by which cancer cells are able to bypass their inhibitory activity.This review intends to present the most recently identified molecular mechanisms that mediate acquired resistance to tyrosine kinase inhibitors, identified through the use of in vitro models or the analysis of patient samples. The knowledge obtained from these studies will help to design better therapies that prevent and overcome resistance to treatment in cancer patients.

PMID:
20385023
PMCID:
PMC2864216
DOI:
10.1186/1476-4598-9-75
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center